ArticleRoyal Society open science2021
Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine.
Article in Royal Society open science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Cardiotoxicity evaluation of two-drug fixed-dose combination therapy under CiPA: a computational study.Translational and clinical pharmacology · 2024Article
- Effects of hydroxychloroquine on atrial electrophysiology in in silico wild-type and PITX2Herz · 2023Article
- Cardiovascular concentration-effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies.British journal of clinical pharmacology · 2023Article
- In silico assessment on TdP risks of drug combinations under CiPA paradigm.Scientific reports · 2023Article
- Characterization of pathological remodeling in the chronic atrioventricular block cynomolgus monkey heart.Frontiers in pharmacology · 2023Article
- Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensiveFrontiers in pharmacology · 2023Article
- Anti-malarial drugs: Mechanisms underlying their proarrhythmic effects.British journal of pharmacology · 2022Review
- Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept.European journal of pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Hydroxychloroquine (HCQ), the hydroxyl derivative of chloroquine (CQ), is widely used in the treatment of rheumatological conditions (systemic lupus erythematosus, rheumatoid arthritis) and is being studied for the treatment and prevention of COVID-19. Here, we investigate through mathematical modelling the safety profile of HCQ, CQ and other QT-prolonging anti-infective agents to determine their risk categories for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.